Format

Send to

Choose Destination
PLoS One. 2016 Feb 4;11(2):e0147183. doi: 10.1371/journal.pone.0147183. eCollection 2016.

Screening of Drug Metabolizing Enzymes for the Ginsenoside Compound K In Vitro: An Efficient Anti-Cancer Substance Originating from Panax Ginseng.

Xiao J1,2,3, Chen D1,2, Lin XX1,2, Peng SF4,5, Xiao MF4,5, Huang WH1,2, Wang YC1,2, Peng JB1,2, Zhang W1,2, Ouyang DS1,2, Chen Y1,2.

Author information

1
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
2
Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, China.
3
Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
4
Department of Hepatology and Infectious Diseases, Xiangya Hospital, Central South University, Changsha, Hunan, China.
5
Health Management Center, Xiangya Hospital, Central South University, Changsha, Hunan, China.

Abstract

Ginsenoside compound K (CK), a rare ginsenoside originating from Panax Ginseng, has been found to possess unique pharmacological activities specifically as anti-cancers. However, the role of cytochrome P450s (CYPs) in the metabolism of CK is unclear. In this study, we screened the CYPs for the metabolism of CK in vitro using human liver microsomes (HLMs) or human recombinant CYPs. The results showed that CK inhibited the enzyme activities of CYP2C9 and CYP3A4 in the HLMs. The Km and Vmax values of CK were 84.20±21.92 μM and 0.28±0.04 nmol/mg protein/min, respectively, for the HLMs; 34.63±10.48 μM and 0.45±0.05 nmol/nmol P450/min, respectively, for CYP2C9; and 27.03±5.04 μM and 0.68±0.04 nmol/nmol P450/min, respectively, for CYP3A4. The IC50 values were 16.00 μM and 9.83 μM, and Ki values were 14.92 μM and 11.42μM for CYP2C9 and CYP3A4, respectively. Other human CYP isoforms, including CYP1A2, CYP2A6, CYP2D6, CYP2E1, and CYP2C19, showed minimal or no effect on CK metabolism. The results suggested that CK was a substrate and also inhibitors for both CYP2C9 and CYP3A4. Patients using CK in combination with therapeutic drugs that are substrates of CYP2C9 and CYP3A4 for different reasons should be careful, although the inhibiting potency of CK is much poorer than that of enzyme-specific inhibitors.

PMID:
26845774
PMCID:
PMC4742234
DOI:
10.1371/journal.pone.0147183
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center